Lisata Therapeutics, Inc. (NASDAQ:LSTA) Shares Shorted: Short Interest Down 76.1% in September

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 39,407 shares, a decrease of 76.1% from the September 15th total of 164,953 shares. Based on an average trading volume of 362,256 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.5% of the shares of the company are sold short.

Lisata Therapeutics Stock Performance

Shares of LSTA remained flat at $1.05 during trading hours on Tuesday. 127,502 shares of the stock were exchanged, compared to its average volume of 192,753. The firm has a fifty day moving average of $1.43 and a two-hundred day moving average of $2.72. The firm has a market cap of $9.46 million, a PE ratio of -0.64 and a beta of 0.94. Lisata Therapeutics has a 1-year low of $0.98 and a 1-year high of $5.07.

Lisata Therapeutics (NASDAQ:LSTA) last released its earnings results on Thursday, August 6th. The company reported ($0.32) earnings per share for the quarter. Sell-side analysts predict that Lisata Therapeutics will post -1.09 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Trading of Lisata Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC increased its holdings in Lisata Therapeutics by 6.5% in the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock valued at $660,000 after buying an additional 8,000 shares during the period. Bank of America Corp DE acquired a new position in shares of Lisata Therapeutics in the 2nd quarter valued at $35,000. SOL Capital Management CO bought a new position in shares of Lisata Therapeutics during the 1st quarter worth about $61,000. BlackRock Inc. bought a new position in shares of Lisata Therapeutics during the 2nd quarter worth about $187,000. Finally, Rangeley Capital LLC acquired a new stake in shares of Lisata Therapeutics during the 1st quarter valued at about $376,000. 8.94% of the stock is currently owned by institutional investors.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies intended to improve the treatment of solid tumors. The company’s approach centers on tumor-penetrating peptides designed to selectively target the tumor microenvironment and help therapeutic agents reach cancer cells more effectively.

Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is designed to activate the CendR pathway, which may increase the penetration and distribution of co-administered anticancer treatments within tumors.